Educational Course on ECP Across GvHD, CTCL, HTx, LUTx Indications

The Goal

To establish a comprehensive understanding of ECP application across GvHD, CTCL, and SOT, including best practices, referral pathways, and THERAKOS™ CELLEX™ Photopheresis System utilization.

Agenda

Download Agenda PDF

Day 1 - 8 October 2026

Arrival of participants

19.00 – 19.30
Meeting in the lobby

19.30
Dinner

Day 2 - 9 October 2026

09:00 – 09:15
Welcome - Therakos International Healthcare Stakeholders Engagement Department

09:15 – 09:30
Introduction - Prof Peter Remenyi

09:30 – 10:30
ECP as a Foundation for GvHD Therapy: Proposed Mechanism of Action - Prof Dr Hildegard Greinix

10.30 – 10.45
Interactive discussion

10:45 – 11:15
Best Practices for the THERAKOS™ CELLEX™ Extracorporeal Photopheresis System - Dr Andrea Várkonyi

11:15 – 11:30
Coffee Break

11:30 – 12:00
Advancing Knowledge on ECP Technology: The CELLEX™ System Across Multiple Indications - Dr Marienn Réti

12:00 – 12:15
Interactive discussion

12:15 – 12:45
ECP Unit Visit

12:45 – 13:45
Lunch

13.45 – 14.15
ECP in Lung Transplantation: Current Approaches to Managing LuTx Complications - Prof Peter Jaksch

14:15 – 14:45
Positioning ECP in the Management of Heart Transplant Recipients: Development of a Referral Pathway - Prof Balazs Sax

14:45 – 15:00
Interactive discussion

15:00 – 15:45
Patient cases discussion

15:45 – 16:00
Final remarks and close - Prof Peter Remenyi

ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease, LuTx: Lung Transplantation, SOT: Solid Organ Transplantation

Please see the THERAKOS™ CELLEX™ Photopheresis System operator’s Manual for indications,contraindications, warnings, precautions, adverse reactions, and other important information.

For this course, participants are required to submit one patient case for discussion 15 days in advance of the session.

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd
This information is intended for healthcare professionals based in Europe and the Middle East.

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

Explore related courses

Oct 21 - 22, 2026

Educational Course on the Management of GvHD

Wellcome Collection, London, United Kingdom

Find out more

Oct 26, 2026

Educational Course on a Multidisciplinary Deep Dive Into IS Sparing Options Across Organ

Hilton Munich Airport, Bavaria, Germany

Find out more

Nov 26 - 27, 2026

Educational Course on Graft‑versus‑Host Disease: Evolving Landscape of GvHD Management

Novotel am Konzerthaus, Freiburg, Germany

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Educational Course on ECP Across GvHD, CTCL, HTx, LUTx Indications

The Goal

Agenda

Day 1 - 8 October 2026

Day 2 - 9 October 2026

Explore related courses

Educational Course on the Management of GvHD

Educational Course on a Multidisciplinary Deep Dive Into IS Sparing Options Across Organ

Educational Course on Graft‑versus‑Host Disease: Evolving Landscape of GvHD Management

Sign in to register your interest

Register your interest in attending